RAPC5-7-156

RAPC5-7-156 is a high-affinity small molecule ligand specifically designed to target G protein-coupled receptor class C group 5 member D (GPRC5D), an orphan receptor that is highly and selectively expressed on the surface of malignant plasma cells in multiple myeloma. Developed by researchers at Memorial Sloan Kettering Cancer Center, RAPC5-7-156 serves as a theranostic scaffold. When conjugated with diagnostic radioisotopes like Gallium-68, it enables positron emission tomography (PET) imaging for the detection and monitoring of myeloma. When conjugated with therapeutic alpha- or beta-emitting isotopes such as Actinium-225 or Lutetium-177, it functions as a targeted radiopharmaceutical to deliver localized radiation to tumor cells. Its small molecular size facilitates rapid blood clearance and deep tissue penetration, potentially offering a favorable safety and efficacy profile compared to antibody-based GPRC5D therapies.